Title: Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Title: Systems Level Studies of Viral Infection: Roles for Site-specific Glycosylation, Biochemical Pathways and Intracellular Lectins
Dr. Sriram Neelamegham is a UB Distinguished Professor of Chemical & Biological Engineering, Biomedical Engineering, and Medicine at the State University of New York-Buffalo. His laboratory works at the interface of engineering and medicine, with applications in studies of human disease mechanics. Such work falls under the umbrella of "Systems Glycobiology," where high-throughput experimentation and mathematical modeling are coupled to describe the interplay between the competing glycoEnzymes that regulate cellular glycosylation patterns. Prof. Neelamegham has published over 140 research articles, book chapters, and patents. He receives the NIH Independent Scientist award, the 2015 State University of New York Chancellor's Award for Excellence in Scholarship and Creative Activities, and the 2018 Schoellkopf medal from the Western New York American Chemical Society. He is an Elected Fellow of the American Institute of Biological and Medical Engineering (AIMBE) and Biomedical Engineering Society (BMES). He has served on NIH advisory panels and editorial boards of various journals. He is currently the Discussion Leader developing the Symbol Nomenclature for Glycans (SNFG) at the NCBI-glycans resource. Before moving to Buffalo. Prof. Neelamegham received his Ph.D. in Chemical Engineering/Bioengineering from the Rice University and completed his post-doctoral training at the Baylor College of Medicine.
Title: Sulfated glycosaminoglycans - Studies in diversity
Dr. Kitagawa received his Ph.D. in Biochemistry in 1991 from Kyoto University. He did his doctoral work in the laboratories of Prof. Ikuo Yamashina and Prof. Toshisuke Kawasaki on the purification and characterization of cancer-associated carbohydrate antigens by using monoclonal antibodies raised against human cancer cells. Dr. Kitagawa went on to do postdoctoral work with Dr. James C. Paulson at Cytel Corporation and Scripps Research Institute. In Dr. Paulson’s laboratory, he worked on the molecular cloning and characterization of several sialyltransferases. In 1994 he obtained an assistant professor position at the Department of Biochemistry, Kobe Pharmaceutical University, where he started to work on the structure and biosynthesis of sulfated glycosaminoglycans. He was promoted to associate professor in 2000 and full professor in 2005. He received the young scientist award of the Japanese Society of Carbohydrate Research in 1999, the PSJ (Pharmaceutical Society of Japan) award for young scientists in 2001, the young investigator award of the Japanese Biochemical Society in 2002, and the PSJ award for Divisional Scientific Promotions in 2013. He has continued to work on the functions and the control of the biosynthesis and degradation of sulfated glycosaminoglycans to clarify the causes of various disorders.
Title: The human gut microbiota-plant cell wall nexus
Dr. Harry Brumer is a Professor in the Michael Smith Laboratories and Department of Chemistry, and an Associate Member of the Department of Botany and the Department of Biochemistry and Molecular Biology, at the University of British Columbia.
Dr. Brumer’s research interests include the discovery, functional and structural characterization, and biotechnological applications of carbohydrate-active enzymes and carbohydrate-binding proteins. Through close collaboration with geneticists and structural biologists, research in the Brumer group seeks to bring molecular-level insight into the biological processes underpinning carbon flux in ecosystems ranging from the forest to the human gut.
Title: Targeting Cancer-Associated Sialylation for Cancer Immunotherapy
Dr. Heinz Läubli received his M.D. and Ph.D. at the Institute of Physiology, University of Zürich (Switzerland). He is now an Assistant Professor and a Research group leader at the University of Basel and an Attending physician in the Division of Oncology, and Head of Glycobiology Research in the Department of Biomedicine, at the University Hospital Basel. Dr. Heinz’s research interests are to improve immunotherapy for cancer patients by using translational in vitro and in vivo tumor models, performing correlative analysis of patients treated with immunotherapy, and conducting early clinical interventional trials. His group has been studying the interaction between siaologlycans and their interaction with Siglec receptors on immune cells. It has demonstrated that this pathway can be targeted to augment T-cell stimulation and tumor control. His research goals also include the improvement of cancer immunotherapy by modifying glycans in the tumor microenvironment and glycans of cellular products for adoptive cell therapies, including genetically modified T cells.
Nagoya University Graduate School of Medicine, Japan
Title: Crosstalk of glycosaminoglycans and cell surface receptors in neural wiring/rewiring
Dr. Kadomatsu started his career in basic medical research after being a physician of pediatric neuroblastoma. During his graduate studies, he discovered the glycan-binding growth factor midkine. He has been researching the involvement of cancer, neurology, and inflammation. For this achievement, he received the Young Investigator Award from the Japanese Biochemical Society in 1997.
His research with a Chinese graduate student led him to become particularly interested in the relationship between glycans and the nervous system, which has become the focus of his research. He was a representative of "Neuroglycobiology" (2011-2015), the Grant-in-Aid for Scientific Research on Innovative Areas by the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). He currently represents the "Human Glycome Project," Roadmap 2020, MEXT.
He served as the President of the Japanese Society of Carbohydrate Research, Editor-in-Chief of the Journal of Biochemistry, and representative of the Asia/Australia/Africa region of the Advance in Neuroblastoma Research Association. He holds an honorary professorship from the Chinese University of Hong Kong.
Title: A Sugar Coat on Neuronal Surface: The Supramolecular Assembly of Glycosaminoglycans and Glycoproteins in Regulating Neuroplasticity
Dr. Jessica Kwok is an Associate Professor in Neuroscience at the University of Leeds. Her lab focuses on elucidating the functions of a pericellular coat called perineuronal net, with the main components being glycosaminoglycans (GAGs) and glycoproteins, in the regulation of neuroplasticity. The role of the GAGs in plasticity and axon regeneration has been the main research topic. In the last ten years, her work has played the key role in establishing the mechanism of PNN formation, the interaction of different PNN molecules, and how the interactions define the PNN structure and exert their effects on plasticity. The work has led to the current widely accepted concept that PNNs are crucial in controlling central nervous system (CNS) plasticity. These concepts allow her to design plasticity enhancement treatment for repairing and recovering deficits in the CNS, with a focus on spinal cord injury and memory enhancement.
Title: Glycans at the Frontiers of Inflammation, Autoimmunity and Cancer: mechanisms and clinical implications.
Salomé Pinho is the coordinator of the research group "Immunology, Cancer & GlycoMedicine" at the Institute for Research and Innovation in Health (i3S) at the University of Porto, Portugal, and affiliated Professor at the Medical Faculty of the University of Porto, Portugal. She developed her Ph.D. research at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Boston University Medical School, MA, USA. She performed her postdoctoral work at IPATIMUP-University of Porto in the cancer glycobiology field. Early in her career, Dr. Pinho established a research line focusing on glycoimmunology in Inflammatory Bowel Disease. Her group focuses on understanding the role of post-translational modifications by glycosylation in the regulation of key proteins´ functions involved in cancer and chronic inflammatory conditions, envisioning potential clinical applications.
She is the Principal Investigator of several national/international grants in cancer glycobiology and inflammatory diseases. She received the Young Investigator Award from the European Association for Cancer Research and was recently distinguished by the Society for Glycobiology with the 2020 Glycobiology Significant Achievement Award.
Title: Human Gut Bacteria Tailor Extracellular Vesicle Cargo for the Breakdown of Diet- and host-derived glycans
Dr. Feldman obtained his Ph.D. at the University of Buenos Aires, Argentina, under the supervision of Dr. Armando Parodi. After completing his postdoctoral training in Guy Cornelis and Markus Aebi labs in Switzerland, he joined the University of Alberta, in Edmonton, Canada, as an assistant professor. In 2015 he moved to the Department of Microbiology at the Washington University School of Medicine in St Louis, USA. The Feldman lab is interested in microbial glycobiology and bacterial pathogenesis. Dr. Feldman has pioneered the field of bacterial glycoengineering, which is a promising approach for the generation of novel bioconjugate vaccines. He has co-founded two companies (VaxAlta and Omniose) in this area. He is a world leader in studying the human pathogen Acinetobacter baumannii and the biogenesis of bacterial extracellular vesicles. Dr. Feldman is a fellow of the American Academy of Microbiology.
Title: Exploring Glycosylation-dependent Pathways as Modulators of Intestinal Inflammation
Dr. Mariño received her Ph.D. in Chemistry from the University of Buenos Aires. She continued her training as a postdoc at the University of Dundee (Scotland, UK) and later, at the National Institute for Bioprocessing, Research, and Training (Dublin, Ireland), integrating her chemical vision of carbohydrates into the biochemistry of glycans and the structural analysis of glycoconjugates in physiological and pathological contexts. After relocating to Argentina, she established the Functional and Molecular Glycomics Lab (Institute of Biology and Experimental Medicine). As an Independent Researcher at CONICET, she focuses on how inflammatory conditions could alter the glycome in inflammatory bowel diseases and colorectal cancer and whether these changes can promote the establishment of altered lectin-glycan interactions and, in doing so, influence the immune response. Her goal is to capitalize on glycoimmunological mechanisms that could potentially re-wire immune circuits in these pathologies, providing novel opportunities for translational medicine.
Based on her glycoanalytical experience, she also offers consultancies on glycosylation analysis to the Latin American Life Sciences Industry. She received several prizes for her work, including the "Carlos B. Udaondo" award from the National Academy of Medicine (2019). She is the current National Representative for Argentina at the International Glycoconjugate Organization.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.
Title: Glycomics-guided glycoproteomics uncovers new players in the innate immune system
Associate Professor Morten Thaysen-Andersen heads the Analytical Glycoimmunology at Macquarie University, Sydney, Australia. Additionally, he was recently recruited as Visiting Professor at Nagoya University, Japan, to set up a Glycoproteomics lab at the prestigious Institute for Glyco-core Research (iGCORE). Across the two laboratories, his glycobiology-focused research program aims to advance our understanding of the human innate immune system and immune-related diseases, including microbial infections, inflammation, and cancer. His team develops and applies novel glycomics and glycoproteomics technologies using advanced mass spectrometry while drawing on analytical tools in protein and carbohydrate chemistry and methods in immunology, structural biology, microbiology, and molecular and cell biology to unravel fundamental glycobiological processes within the innate immune system.